Novartis Officially Opens $1 Billion Vaccine Manufacturing Plant in North Carolina
The plant's opening marks the first change in influenza vaccine manufacturing in the United States in 50 years. Specifically, it's the first American plant capable of quickly producing pandemic and seasonal influenza vaccines using cultured animal cells rather than fertilized eggs. This new cell-based technology also may be adapted to produce large amounts of vaccines for other emerging infectious diseases.
Located on 167 acres, the Holly Springs site consists of six connected buildings comprising 430,000 square feet of manufacturing, laboratory and office space. Novartis employs about 400 colleagues here, and has plans to expand to 500 workers by year-end 2012.
"The pandemic readiness of this facility is a major milestone in national preparedness for pandemic influenza and other diseases," noted Robin Robinson, Ph.D., director of the Biomedical Advanced Research and Development Authority (BARDA) associated with HHS. Officials estimate it might be capable of producing one-fourth of the vaccine needed in America during an influenza pandemic. Relatedly, North Carolina State University is working with Novartis and BARDA to educate scientists from around the world about the plant's advanced manufacturing processes. This training should further advance efforts to stem regional and global spreading of deadly illnesses, both known and unknown.
E. & J. Gallo Winery Plans Chester County, South Carolina, Production Center & Distribution Hub
A Turnkey Approach to Manufacturing Location Decisions
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Life Sciences Fueling Construction Demand
What’s Driving Record Industrial Real Estate Demand
In Focus: The Effects of the Pandemic on Industrial Design
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts